[
  {
    "section": "section:1",
    "title": "Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib"
  },
  {
    "section": "section:2",
    "title": "PATIENTS AND METHODS"
  },
  {
    "section": "section:3",
    "title": "Initial Study Design"
  },
  {
    "section": "section:3",
    "title": "Amended Design"
  },
  {
    "section": "section:3",
    "title": "Mutational Analysis"
  },
  {
    "section": "section:2",
    "title": "RESULTS"
  },
  {
    "section": "section:3",
    "title": "Dasatinib 70 mg Twice Daily"
  },
  {
    "section": "section:3",
    "title": "Dasatinib 100 mg Daily \u0002 Erlotinib"
  },
  {
    "section": "section:3",
    "title": "Toxicities"
  },
  {
    "section": "section:2",
    "title": "DISCUSSION"
  },
  {
    "section": "section:2",
    "title": "ACKNOWLEDGMENTS"
  },
  {
    "section": "section:2",
    "title": "REFERENCES"
  }
]